Targeted Oncology: Data Shows How Ruxolitinib is the Cornerstone of Treatment in Myelofibrosis Shared By: contributorSeptember 12, 2022 Ruben Mesa, MD, Mays Cancer Center, was interviewed for this article. Watch Video Share This Article!
